Treatment of Chalazian: a Comparative Cross-sectional Study
Keywords:
Chalazion, Intralesional Triamcinolone Acteonide, Incision and Curettage, Meibomian GlandAbstract
Introduction: Chalazion is a common eyelid margin disorder manifesting as granulomatous inflammation associated with meibomian gland lipids. There are three methods of treating chalazian: Intralesional
Triamcinolone Acetonide (0.1-0.3 ml of 40mg/ml), Incision and Curettage and Conservative Treatment (hot compression +lid hygiene + antibiotic ointment).
Methods: Patients with chalazian presenting to the Outpatient Department (OPD) of the Lumbini Eye Institute and Research Center (LEIRC) from 15 March 2017 to 15 July 2017 were included in the study. They underwent
any of the three procedures (Conservative Treatment or Triamcinolone Acetonide Injection or Incision and Curettage) according to their choice. We compared all three methods of treatment of chalazion on follow up
visit at 2 weeks, which was done to determine effectiveness in terms of reduction of size or complete resolution of the chalazia.
Results: Out of 112 patients enrolled in study 65(58%) were females and 47(42%) were male with a male: female ratio of (0.7:1). The mean age of involvement was 25.7years (SD 10.3). At 2 weeks follow up there was
complete resolution in incision and curettage (I and C) group 77 % (41/53) and in Triamcinolone Acetonide (TA) injection group 63 %( 20/32). Pearson’s correlations showed that I and C were superior to any other forms of intervention for any size of chalazian followed by intralesional injection of TA.
Conclusion: Incision and Curettage remained the best choice for the treatment of chalazion followed by triamcinolone acetonide injection but may need multiple injections.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
All articles published in EJMS are licensed under the Creative Commons Attribution 4.0 International License (CC-BY 4.0). The author(s) as the copyright holder will retain the ownership of the copyrights without any restrictions for their content under the CC-BY 4.0 license, and allow others to copy, use, print, share, modify, and distribute the content of the article even in commercial purpose as long as the original authors and the journal are properly cited. No permission is required from the author/s or the publishers. Appropriate attribution can be provided by simply citing the original article.
On behalf of all the authors, the corresponding author is responsible for completing and returning the agreement form to the editorial office. More information about the terms and conditions, privacy policies, and copyrights can be found on the webpage of the Creative Commons license privacy policy. https://creativecommons.org/licenses/by/4.0/
